USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences

Q: Where does Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences ranks #39,384 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

Q: Is Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences.

Q: How is the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 6 granted patents across 9 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Center ranks #39,384 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 9 technology areas.

#39,384
of 49,997 US assignees by volume: Top 30%
by Innovation Score (42.7/100): 9.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R39384 · Foreign Corporation #39,384 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #39,384/49,997
PHOTO-FINISH CellMobility
CPC-NARROW A61P · 9 areas
INNOV-PAR 42.7/100
CLAIMS-PAR 9.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: CellMobility, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Center’s 42.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (16%) Velocity 20.0 pts (47%) Breadth 10.6 pts (25%) Claim depth 5.4 pts (13%)

Qualcomm Incorporated · highest

85
Center for Excellenc… · this assignee

43
3D Lighting… · lowest

7

What this shows Center's Innovation Score is 42.7/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Center?

Each dot is one of Center’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Center’s own 9.0 claims/patent is at or below the 13.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Center vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Center's grants concentrate

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences is a focused PatentsView assignee: 9 CPC subclasses with 66.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (2 grants) versus a trough of 1 in 2022. By volume, Center sits between CellMobility, Inc. and Ceres Technologies, Inc..

Center's three-year grant acceleration

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cellmobility

6
Cellmosaic

6
Centauri Therapeu…

6
Center for Deep L…

6
Centrotherm Photo…

6
Cerasina

6
Cerebrotech Medic…

6
Ceres

6
Center for Excell… ◀

6

What this shows Center holds 6 patents at rank #39,530, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Center

By rank, the assignees closest to #39,530 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Center's primary technology class.

Center's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	1	16.7%
2023	1	16.7%
2024	2	33.3%
2025partial year	2	33.3%

Which technologies does Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C07K - Peptides 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences's patent record in context - here's where to go next.

Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 66.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #39,384 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences against CellMobility, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.